Drug Approval | December 23, 2023
Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Softovac Liquifibre expands the Softovac product portfolio and provides a choice for consumers who prefer time-tested Ayurvedic ingredients
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
Methylene blue is a cationic thiazine dye that necessitates specialised capabilities and expertise to develop and manufacture the product
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
OCEANIC-AF is one trial which evaluates asundexian versus apixaban in patients with atrial fibrillation at risk for stroke within the overall OCEANIC phase III program
Subscribe To Our Newsletter & Stay Updated
